Improvement of Therapeutic Effect via Inducing Non-Apoptotic Cell Death Using mRNA-Protection Nanocage

Area of Science:

• Biomedical Engineering
• Nanomedicine
• Cancer Biology

Background:

• Necroptosis, a regulated form of necrosis, is a promising cancer therapy target.
• Receptor-interacting protein kinase-3 (RIPK3) is a key factor in necroptosis induction.
• Current mRNA delivery methods face challenges with degradation and low efficiency.

Purpose of the Study:

• To develop an effective mRNA delivery system for cancer therapy.
• To investigate the potential of RIPK3 mRNA delivery via nanocarriers for necroptosis induction.
• To evaluate the therapeutic efficacy of this approach in preclinical cancer models.

Main Methods:

• Development of mRNA-protective nanocages (mPN) using nanostructured silica nanoparticles.
• Delivery of in vitro transcribed (IVT) RIPK3 mRNA using mPN in vitro and in vivo.
• Assessment of RIPK3 expression, necroptosis induction, immune cell infiltration, and tumor growth suppression.

Main Results:

• High-efficiency RIPK3 expression and necroptosis induction were achieved using mPN.
• mPN effectively delivered RIPK3 mRNA to tumors, inducing necroptosis and immune cell infiltration.
• Significant suppression of tumor growth was observed in a murine cancer model, indicating synergistic effects.

Conclusions:

• mRNA-protective nanocages (mPN) offer a viable strategy for delivering RIPK3 mRNA to induce necroptosis for cancer therapy.
• This nanomedicine approach demonstrates potential for synergistic anticancer effects by combining direct tumor cell death with immune stimulation.
• The findings support the development of mRNA-based nanomedicines for advanced cancer treatment.